We are live on ! Find out more
SBIO icon

ALPS Medical Breakthroughs ETF
SBIO

Fund managers haven’t disclosed any holdings of SBIO yet.

SBIO Hedge Fund Activity: Q1 2026 in Review

59 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in ALPS Medical Breakthroughs ETF (SBIO) for Q1 2026, worth a combined $43.7M — down 45% from $78.8M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new SBIO positions and 8 closed out — a net gain of 4 holders — while 16 added to existing stakes and 14 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $3.09M. The largest seller was Phoenix Financial, exiting entirely with an estimated $38.3M sold.

  • 59 institutional investors held ALPS Medical Breakthroughs ETF (SBIO) as of Q1 2026, up from 58 in Q4 2025.
  • Funds reported $43.7M of ALPS Medical Breakthroughs ETF stock for Q1 2026, down 45% quarter-over-quarter.
  • 12 funds opened new ALPS Medical Breakthroughs ETF positions in Q1 2026 and 8 closed out, a net change of +4 holders.
  • The largest ALPS Medical Breakthroughs ETF buyer in Q1 2026 was Susquehanna International Group, an estimated $3.09M added.
  • The largest ALPS Medical Breakthroughs ETF seller in Q1 2026 was Phoenix Financial, an estimated $38.3M sold.

Based on aggregated 13F filings for Q1 2026.